Research across Cancer
Related studies from across the Cancer family.
Rezvilutamide plus ADT with efavirenz-based ART yields PSA decline in one HIV-positive mHSPC patient
Rezvilutamide Shows Promise for Prostate Cancer in HIV Patients
This is a single-patient case report describing rezvilutamide plus androgen deprivation therapy in an HIV-positive patient with high-volume …
A single patient with both HIV and advanced prostate cancer showed significant improvement after starting a specific combination of treatmen…
Docetaxel and PARPi additions to ARPI and ADT improve progression-free survival in mHSPC
New data shows potential benefits for advanced prostate cancer patients
This network meta-analysis of 18,689 patients with metastatic hormone-sensitive prostate cancer (mHSPC) evaluated first-line systemic combin…
New data suggests that adding specific drugs to standard hormone therapy may help slow the growth of advanced prostate cancer.
Integrated Prognostic Criteria Improve Survival Stratification in Metastatic Castration-Sensitive Prostate Cancer
Trial shows improved prediction of survival in prostate cancer
Combining CHAARTED and LATITUDE criteria enhances prognostic accuracy for mCSPC, though specific treatment benefits in certain subgroups rem…
A new way to combine two scoring systems helps doctors better predict how patients with advanced prostate cancer will respond to treatment.
Lead-in ADT reduces grade ≥3 neutropenia incidence in metastatic hormone-sensitive prostate cancer patients
Lead-in therapy may reduce severe low white blood cell counts
This post hoc analysis of a phase 3 trial and real-world validation study evaluated lead-in androgen-deprivation therapy (ADT) for patients …
A new look at clinical data suggests that a lead-in hormone treatment can help prevent serious low white blood cell counts in prostate cance…
Hypofractionated and dose-boosted radiotherapy improves metastasis-free survival in clinically localised prostate cancer
Dose-boosting radiotherapy may improve survival for high-risk prostate cancer patients
This systematic review and meta-analysis evaluated hypofractionated and dose-boosted radiotherapy fractionation schedules versus standard ra…
Combining external beam radiotherapy with brachytherapy or a focal boost significantly improved metastasis-free survival in patients with cl…
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
Time to biochemical progression predicts second events in high-risk prostate cancer
Longer time to progression predicts better outcomes in prostate cancer
This phase 3 RCT of 413 men with high-risk localized prostate cancer found that a longer time from randomization to biochemical progression …
Men with high-risk prostate cancer who had a longer time before their cancer worsened were less likely to have further progression or spread…